Biotechnology

Thursday May 25, 2023 - 12:03 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, has enrolled 134 patients. This represents more than 50%…

Wednesday May 24, 2023 - 11:40 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the first participants have been dosed with CYB004 in its ongoing three-part phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers. No safety concerns were reported from the initial participants…

Monday May 22, 2023 - 1:45 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Looking to Complement Core Focus with CDMO Offering

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company aims to complement its core focus, nanosized antibody (“NanoAb”) pipeline development, with a comprehensive CDMO (contract development and manufacturing organization) offering. “With significant experience including developing its previous flu vaccine candidate, BiondVax intends to share its expertise, human…

Monday May 22, 2023 - 9:24 am

InvestorNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Releases Details of Common Share Offering

Universal Ibogaine (TSX.V: IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, has announced an offering of up to 66,666,667 shares. The shares will be offered $0.03 per share, which could result in approximately $2 million in gross proceeds. According to the announcement, each unit will include one common share and a one-half common share purchase warrant, with each whole warrant…

Friday May 19, 2023 - 12:01 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at an upcoming Water Tower Research Fireside Chat Series. The company announced that CEO Eric A. Adams will be the featured speaker at the May 23, 2023, fireside chat; the event is slated to begin at 1 p.m. ET. During the chat,…

Thursday May 18, 2023 - 12:53 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its HeartBeam AIMIGo(TM) System. The HeartBeam AIMIGo System is a personal, portable and easy-to-use VECG solution to assist patients and their clinicians in…

Thursday May 18, 2023 - 12:05 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Participation at Upcoming LD Micro Invitational

IGC Pharma (NYSE American: IGC) will be presenting at the 13th annual LD Micro Invitational, which is slated for June 6–8, 2023, in Los Angeles. IGC Pharma CEO Ram Mukunda and PFO Claudia Grimaldi will be leading the presentation, which is scheduled to begin at 3 p.m. PT on June 6. The event is in person, although individual presentations can be viewed virtually. An estimated…

Tuesday May 16, 2023 - 11:10 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company has been awarded approximately C$2.81 million in an arbitration settlement. An InvestmentPitch Media video provides additional information about this news and the company. The video is available for viewing on…

Tuesday May 16, 2023 - 10:58 am

InvestorNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Releases Q1 2023 Financial, Corporate Update Report

NextPlat Corp. (NASDAQ: NXPL), a global e-commerce provider, is reporting on its financial results for the three months ended March 31, 2023. The report also noted that the company is looking to drive future growth by adding healthcare and an Alibaba Tmall Global partnership. Financial highlights for first quarter of 2023 include revenues of approximately $2.9 million, an increase of 26% from the core revenue…

Tuesday May 16, 2023 - 9:31 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting its financial results for the first quarter ended March 31, 2023; the report also noted key business updates. Highlights of the report indicate R&D expenses for quarter totaled $2 million with marketing, general and administrative expenses for the quarter reaching…

Monday May 15, 2023 - 2:57 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment…

Monday May 15, 2023 - 12:23 pm

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Reports on Q1 2023 Financial Results

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has release a report on its first-quarter revenues for the period ended March 31, 2023. The company reported revenues for the quarter totaled $1,121,676, compared to $721,629 in Q1 2022. Operating expenses for the quarter came in at $1,496,537, compared to $2,978,933 for the same period in 2022, and net losses…

Monday May 15, 2023 - 12:04 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2023. In addition, the company provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer.…

Monday May 15, 2023 - 10:10 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that a complaint against the company and its subsidiary, FSD Biosciences Inc., was filed on May 1, 2023. The complaint was filed in the United States District Court for the Southern…

Thursday May 11, 2023 - 12:17 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced that in a cost award decision dated May 6, 2023, the Honorable J. Douglas Cunningham, K.C. (“Justice Cunningham”) ruled in favor of FSD Pharma, awarding the company approximately…

Wednesday May 10, 2023 - 12:14 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has completed dosing the first cohort of patients in its phase I clinical trial of Lucid-21-302 (Lucid-MS). According to the announcement, the study, which is being conducted by Lucid Psycheceuticals, the company’s wholly…

Tuesday May 09, 2023 - 12:19 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has received a patent from the U.S. Patent and Trademark Office (“USPTO”). Titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,” the patent claims cover the use of biomarkers in determining the efficacy of SILO’s portfolio drug SPC-15. SPC-15 is a targeted prophylactic treatment that uses…

Monday May 08, 2023 - 1:41 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced that Zeeshan Saeed, president and executive co-chairman, and Dr. Lakhsmi Kotra, executive director and CEO of Lucid Psycheceuticals, will present and host one-on-one meetings with investors at the…

Monday May 08, 2023 - 9:00 am

InvestorNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer

INmune Bio (NASDAQ: INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease, announced that its Investigational New Drug (“IND”) application for INKmune(TM), a novel natural killer (“NK”) cell immunotherapy, has been cleared by the U.S. Food and Drug Administration (“FDA”) for a phase 1/2 open-label clinical trial for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”). According to…

Friday May 05, 2023 - 1:07 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Inks Stiff Person Syndrome Clinical Trial Agreement with Mayo Clinic

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, and its subsidiary Adimune(TM) Inc. announced a clinical trial agreement with Mayo Clinic. The clinical trial, which is designed to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”), is expected to begin this year with an estimated 10 to 15 patients, some of…

Thursday May 04, 2023 - 12:02 pm

InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference

NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; his presentation is scheduled May 10. The global conference is…

Wednesday May 03, 2023 - 1:13 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes $25M Capital Raise to Achieve Upcoming Milestones, Extend Cash Runway

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions. The company today announced the closing of its secondary offering of 16,666,666 shares of HeartBeam’s common stock. According to the update, the financing will allow HeartBeam to fund its upcoming…

Wednesday May 03, 2023 - 12:16 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is investigating potential naked short selling of its stock. As part of that process, the company has retained Shareholder Intelligence Services LLC (ShareIntel), a well-known analytics firm. ShareIntel will be evaluating trading patterns of CNSP stock as part of…

Monday May 01, 2023 - 9:35 am

InvestorNewsBreaks – Artella Solutions Inc. Names New Leadership Team Members, Announces Six-State Expansion

Artella Solutions, a company committed to advancing the well-being of patients with rhythm disorders while providing high-quality, real-time data to physicians for immediate viewing, announced that several industry veterans have joined the company’s national sales team as the Texas-based organization expands into six new markets: Arizona, Florida, Ohio, Michigan, New York and Pennsylvania. The strategic expansion is based on Artella’s best opportunities to capture market…

Tuesday Apr 25, 2023 - 10:15 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered direct offering. The company transacted the closing with a single healthcare-focused institutional investor; the closing consisted of the purchase and sale of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof), which were made…

Friday Apr 21, 2023 - 1:48 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, the study will also enroll patients who have received additional…

Thursday Apr 20, 2023 - 9:50 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Inks Asset Purchase Agreement for 50% Ownership of Global Response Aid

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According to the announcement, the agreement gives Aditxt a 50% ownership in G Response Aid FZE; the remaining 50% ownership belongs to global logistics leader Agility Inc. Calling the agreement a “significant step” for the company, Aditxt officials…

Wednesday Apr 19, 2023 - 11:12 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in an equity research report published by Aegis Capital Corp. In the report, Aegis Capital maintained a buy rating for BVXV at a $70 target price. The publication reads, “R&D expenses for 2022 of $5.8 million were in-line with…

Tuesday Apr 18, 2023 - 9:51 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, published its full-year financial results for the year ended December 31, 2022; the report also included key business updates. Highlights of the report include the signing of definitive agreements with the Max Planck Society (“MPG”) and the University Medical Center…

Monday Apr 17, 2023 - 1:09 pm

InvestorNewsBreaks – Progressive Care Inc. (RXMD) Identified as a High-Growth Opportunity

Progressive Care (OTCQB: RXMD) offers services and technology that supports the managed health care industry to reduce costs and improve the quality of care. “The company has been steadily building both its pharmacy and data-management divisions as revenues continue to improve. However, a couple of extremely revealing events recently transpired that may have set the course for considerable upside potential. “The first inkling of something…

Monday Apr 17, 2023 - 10:28 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Shareholder Update on Major Programs, M&A Plans

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three innovation programs and strategic M&A initiatives. The update notes that subsidiary Pearsanta submitted a bid to acquire substantially all assets of Lucira Health Inc., including Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. The company was…

Friday Apr 14, 2023 - 11:30 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “In many compelling ways, BiondVax punches well above its weight compared to biopharma companies of similar market cap: BiondVax gained extensive drug development expertise [through previous clinical trials evaluating the M-001 universal influenza vaccine candidate], which is expected to be…

Wednesday Apr 12, 2023 - 12:59 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Spin-Out Plan, Announces Shareholder Meeting

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, plans to complete its spin-out transaction outlined in a plan of arrangement. The plan called for shares of the yet-to-be-formed wholly owned subsidiary to be separated into an independent public company. According to…

Monday Apr 10, 2023 - 1:06 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that more than 100 patients have been enrolled in the company’s potentially pivotal study with its lead product candidate, Berubicin. “We have long promised a study with a robust sample size sufficient to effectively determine Berubicin’s therapeutic…

Thursday Apr 06, 2023 - 12:28 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the update, the company plans to open its clinical sites in Italy…

Monday Apr 03, 2023 - 2:56 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that…

Friday Mar 31, 2023 - 3:31 pm

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW), Jupiter Wellness Acquisition Corp. Schedule Special Meeting for Approval of Proposed Business Combination

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, is reporting that the U.S. Securities and Exchange Commission ("SEC") has declared effective its registration statement. Jupiter Wellness, the business combination sponsor, observed that the registration statement was regarding Chijet Motor Company Inc., a developer of next-generation electric vehicles, in connection with a previously announced proposed business combination with Jupiter Wellness…

Thursday Mar 30, 2023 - 2:28 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Offer Timely Solution amid a ‘Smoldering Public Health Crisis’

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere. “A recent study shows that risk factors for cardiovascular (‘CV’) disease are rising among young adults… ‘Yet medical treatment rates for CV risk factors are ‘surprisingly low among young adults,’ study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and…

Thursday Mar 30, 2023 - 12:10 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Board Appointment of Gerry David

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the appointment of Gerry David to its advisory board. David is best known for his five-year tenure as CEO at zero-calorie fitness drink maker Celsius Holdings Inc., where he spearheaded a…

Monday Mar 27, 2023 - 2:36 pm

InvestorNewsBreaks – Titan Partners Group LLC Announces Appointment of Life-Sciences Expert Dr. David Sans

Titan Partners Group, a division of American Capital Partners LLC (“Titan Partners”), today announced that Dr. David Sans has joined the firm as head of healthcare. Dr. Sans will lead the team that covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors. “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions